POSNOC (Positive Sentinel Node – a randomised trial of adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy)

POSNOC（前哨淋巴结阳性 - 单独辅助治疗与辅助治疗加清除或腋窝放疗的随机试验）

• 批准号: nhmrc : GNT1083172
• 负责人: A/Pr Ian Campbell
• 金额: $ 121.07万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/posnoc-positive-sentinel-axillary-radiotherapy/1345494
• 关键词: POSNOC; Positive; Sentinel; Node; randomised

POSNOC (POsitive Sentinel NOde – adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy) will address the key unresolved challenge in breast cancer surgery. A controversial US trial, ACOSOG Z0011, indicates that many breast cancer patients with limited disease in the sentinel node can safely avoid further nodal surgery. This would be a major advance, but there is widespread doubt that the results are broadly applicable. POSNOC will clarify this key issue.

POSNOC（阳性前哨淋巴结-单独辅助治疗与辅助治疗加清除或腋窝放疗）将解决乳腺癌手术中关键的未解决的挑战。一项有争议的美国试验ACOSOG Z 0011表明，许多前哨淋巴结病变有限的乳腺癌患者可以安全地避免进一步的淋巴结手术。这将是一个重大的进步，但人们普遍怀疑这些结果是否广泛适用。POSNOC将澄清这一关键问题。